Shares of biopharmaceutical company PTC Therapeutics (NASDAQ:PTCT) are tanking today after it announced a halt to the Phase 2 study of PTC518 for treating Huntington’s disease.
The development comes after the U.S. Food and Drug Administration (FDA) asked for additional data before allowing the trial to proceed in the U.S.
The company remains in discussions with the FDA and aims to share data from the 12-week part of the study in H1 2023.
Read full Disclosure